StackItSmart

Compound reference

Exemestane

Aromasin

Ancillary compounds1 cited findingClinical review: not reviewed

Pharmacokinetics

Human randomized studyAbstract inspected

A short study in young males found estrogen suppression with oral exemestane and reported an approximately 8.9-hour terminal half-life in its pharmacokinetic subgroup. That finding should not be combined uncritically with values from other populations or used as a duration of estrogen suppression.[1]

  • Short study including adolescents (ages 14-26); no long-term bone, fertility or cardiovascular outcomes. Affiliation/funding erratum inspected; it does not affect the efficacy/PK results.
  • Abstract-checked; full paper not confirmed open access as of 2026-09-09. No qualified clinical review.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independent source inspection; applicability narrowed and inherited assertions excluded where unsupported. No qualified clinical review.

· Reopened the abstract on 2026-09-09 (NCBI efetch) and re-confirmed the exact half-life figure and the 2004 erratum's limited scope (affiliation/grant attribution only). Text unchanged.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Narrowly supported passages published with study/product limits; remaining inherited assertions withheld from established-fact displays.

  • Not a comprehensive systematic review. Original monograph topics beyond the individual published claims—including monitoring schedules, contraindication lists, recovery assurances and detailed mechanisms—remain unverified.
  • No qualified clinician has reviewed these claims. Long-term outcomes and all marketed formulations have not been fully assessed.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

  1. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males.

    Mauras N, Lima J, Patel D, Rini A, di Salle E, Kwok A, Lippe B. J Clin Endocrinol Metab. 2003;88(12):5951-5956. DOI: 10.1210/jc.2003-031279. 2003-12. PMID:14671195 · DOI:10.1210/jc.2003-031279 Abstract only.

    Inspected location: PubMed abstract: full Results (25 mg: 38% estradiol suppression, P<=0.002; 50 mg: 32% suppression, P<=0.008; testosterone increase 60%/56%, P<=0.003 both; terminal half-life 8.9 h; maximal estradiol suppression 62+/-14% at 12 h; lipids/IGF-1 unaffected) and Methods (crossover, PK subgroup)

    Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts
  • Fresh PubMed EUtils retrieval for inherited lead PMID 14671195; identity, abstract and linked corrections checked where an abstract existed.
  • https://pubmed.ncbi.nlm.nih.gov/14671195/ — abstract; PubMed abstract: Methods: crossover and pharmacokinetic subgroup; Results: terminal half-life and estrogen suppression

View this compound in the research library →

Related records in this class

Grouped under Ancillary compounds for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.

StackItSmart

Age confirmation

This reference discusses steroids, SARMs and other compounds. It is educational, not medical advice, and does not recommend using or combining them.

Your confirmation is saved in this browser when storage is available.